Medical Biomimetics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Orthopaedic, Ophthalmology, Dental, Cardiovascular, Others), By Application (Plastic Surgery, Wound Healing, Tissue Regeneration, Others), and By Region Forecast 2020-2031

Medical Biomimetics Market size was valued at US$ 38.6 billion in 2024 and is expected to reach US$ 65.3 billion by 2031, growing at a significant CAGR of 7.8% from 2025-2031. Biomimetics is an innovative design concept that uses natural components and processes to solve complicated human challenges. Medical biomimetics is utilized to address issues linked to cardiac, ocular, orthopaedic, and dental illnesses. Medical biomimetics is used to deliver medications and regenerate tissue. The medical biomimetics business has grown due to an increase in the prevalence of heart disease and dental illness. Dental biomimetic is used to replace lost teeth and reconstruct the jaw before placing dentures.

As a result, the rising prevalence of dental disorders such as dental caries, as well as periodontal diseases such as gingivitis and periodontitis, drives up demand for medical biomimetics. Furthermore, the rise in the trend of biomimetics products, the increase in awareness regarding biomimetics products in developing countries, the increase in the number of clinical trials of biomimetics products, and the rise in the discovery and development of effective medical biomimetics products drives the growth of the market.

Key Developments:

• In November 2021, Otsuka Medical Devices Co., Ltd. introduced the BioMimics 3D Vascular Stent System. This substance assisted in the treatment of acute blockages caused by a patient's unsatisfactory treatment.
• In November 2022, BioMimics 3D's US launch Veryan Medical had announced the launch of their unique BioMimics 3D Vascular Stent System in the United States. The BioMimics 3D self-expanding nitinol stent is a highly differentiated, helical center-line design that has produced good clinical results in clinical studies, including a pivotal study with a three-year follow-up.
• In February 2024, Affluent Medical, based in Aix-en-Provence, France, announced positive clinical evaluation results for its Epygon device, designed to replace mitral valves in patients with mitral insufficiency. Epygon is the first biomimetic transcatheter mitral valve engineered to mimic the native mitral valve and restore the natural vortex of blood flow in the left ventricle. The transcatheter implantation technique allows for a rapid, minimally invasive procedure, helping patients avoid open-heart surgery.
• In February 2024, Biomimetic Innovations Ltd announced that its OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler had received ‘Breakthrough Device’ designation from the FDA. This designation recognizes OsStic® as an innovative solution with the potential to offer more effective treatment options for patients with significant unmet medical needs.
• In January 2025, Sanara MedTech Inc., a Fort Worth, Texas–based medical technology company focused on surgical, chronic wound, and skincare markets, announced that it had executed an exclusive license and distribution agreement with Biomimetic Innovations Ltd (BMI), a privately held medical device company headquartered in Shannon, Ireland. As part of the arrangement, Sanara agreed to invest up to €8.0 million in cash in exchange for approximately 12.5% equity stake in BMI. The initial investment included €4.0 million, which comprised €1.0 million in converting debt, while the remaining €4.0 million will be provided upon achieving specific development, clinical, and regulatory milestones.

Medical Biomimetics Market Segmentation:

Based on the product type:

• Orthopaedic
• Ophthalmology
• Dental
• Cardiovascular
• Others

Among product types, orthopaedic biomimetics currently lead the market, driven by the high demand for advanced bone and joint repair solutions. Orthopaedic biomimetic products, such as bone graft substitutes, cartilage scaffolds, and bio-inspired implants, offer improved integration with natural tissues, enhanced durability, and reduced recovery time compared to traditional implants. Rising incidences of osteoarthritis, sports injuries, and age-related bone degeneration are fueling this growth, particularly in aging populations across developed and emerging economies.

Furthermore, increasing preference for minimally invasive surgical techniques and advancements in regenerative materials support broader adoption. As a result, orthopaedics remains the dominant segment, attracting significant investment and clinical research focus.

Based on the application:

• Plastic Surgery
• Wound Healing
• Tissue Regeneration
• Others

Among applications, tissue regeneration holds the leading share in the market, driven by growing demand for solutions that can restore or replace damaged tissues and organs. Biomimetic products used in tissue regeneration are designed to closely mimic natural biological structures and processes, supporting better cell growth, integration, and functional recovery. Rising cases of chronic diseases, traumatic injuries, and age-related tissue degeneration have significantly increased the need for advanced regenerative therapies worldwide.

Additionally, advancements in stem cell research, 3D-printed scaffolds, and growth factor delivery systems are further propelling adoption. As patients and healthcare providers increasingly prioritize long-term healing and minimally invasive solutions, tissue regeneration continues to dominate, attracting strong clinical and commercial interest.